Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series

We reported on five people with MS, using immunodepleting disease modifying treatments (anti-CD20 monoclonal antibodies and sphingosine-one-phosphate modulators) and with reduced COVID-19 vaccine response, who had mild-to-moderate symptomatic COVID-19, and were treated with anti-SARS-CoV-2 monoclona...

Descripción completa

Detalles Bibliográficos
Autores principales: Moccia, Marcello, Buonomo, Antonio Riccardo, Scotto, Riccardo, Viceconte, Giulio, Nobile, Mariano, Lanzillo, Roberta, Brescia Morra, Vincenzo, Gentile, Ivan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Clinical Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159779/
https://www.ncbi.nlm.nih.gov/pubmed/35689866
http://dx.doi.org/10.1016/j.jns.2022.120306
Descripción
Sumario:We reported on five people with MS, using immunodepleting disease modifying treatments (anti-CD20 monoclonal antibodies and sphingosine-one-phosphate modulators) and with reduced COVID-19 vaccine response, who had mild-to-moderate symptomatic COVID-19, and were treated with anti-SARS-CoV-2 monoclonal antibodies. In particular, we showed the possibility to use monoclonal antibodies to speed-up recovery from COVID-19 in MS, in the absence of any COVID-19 residuals or MS changes (e.g., relapses or disability).

Ejemplares similares